Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III…
By J. Paavonen, D. Jenkins, F. Bosch, P. Naud, J. Salmerón, C. Wheeler, S. Chow, D. Apter, H. Kitchener, X. Castellsagué and 14 more. The Lancet, 2007
1,357 citations recorded by the source corpus.
Subfields: Epidemiology, Microbiology, Otorhinolaryngology
View Paper: https://www.semanticscholar.org/paper/e7d8628935b98b35631cb12d90583146977220c9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Otorhinolaryngology
Citations in the corpus
- Self-assembling protein nanoparticles in the design of vaccines (2015, neutral): “Structural proteins fromdifferentmicroorganisms have served as templates for the production of such nanoparticles and for the presentation of immunogenic epitopes: the protein pIII of the filamentous phage f1 [18], the Ty component from Saccharomyces cerevisiae [19], the surface and core antigens of”
- A review of clinical trials of human papillomavirus prophylactic vaccines. (2012, background): “A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Table 2 Characteristics of phase III efficacy studies in young women Characteristic Future I Future II PATRICIA CVT Vaccine Gardasil® Gardasil® Cervarix® Cervarix® Funding source Merck & Co., Inc. Merck & Co., Inc. Glaxo”